Skip to main content
. Author manuscript; available in PMC: 2009 Jan 1.
Published in final edited form as: J Neuroimmunol. 2007 Dec 11;193(1-2):68–76. doi: 10.1016/j.jneuroim.2007.10.016

Fig. 4. Response of CD8+ IRBP161-180-specific T cells to H-2Dr/IRBP-derived peptide complexes in vitro.

Fig. 4

The proliferative response of 4 × 105 in vivo primed CD8+ IRBP161-180-specific T cells to IRBP-derived peptide-complexed or non-complexed recombinant H-2Dr molecules (10 μg/ml) was tested in the absence or presence of B7 molecules in the thymidine incorporation assay. The results shown are representative of those for 4 separate tests.